



PRESS RELEASE

innate pharma

INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, April 17, 2009

Innate Pharma (Euronext Paris: FR0010331421 – IPH), a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases, announces it will participate to the following analyst and investor conferences in the coming weeks:

- **BioCapital Europe, April 21, 2009, in Amsterdam, The Netherlands;**
- **C,F&B Smallcap Event, April 27-28, 2009, in Paris, France;**
- **BioEquity Europe, June 9-10, 2009, in Munich, Germany.**

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innate-pharma.com) and contact the investor relations team by writing to investors@innate-pharma.com.



PRESS RELEASE

innate pharma

About Innate Pharma

Innate Pharma S.A. (the "Company") is a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, it was initially listed on NYSE-Euronext in Paris in 2006.

The Company has a significant expertise in bringing novel targets to the clinical proof-of-concept trials of drug candidates. It currently has seven proprietary drug-candidates (two of which in clinical trials) and two programs out-licensed to Novo Nordisk A/S.

Based in Marseilles, France, Innate Pharma had 89 employees as at December 31, 2008.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information

ISIN code FR0010331421

Ticker code IPH

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Innate Pharma to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Laure-Hélène Mercier,
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
lmercier@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Phone: +33 (0)1 41 22 07 31
Mob: +33 (0)6 64 18 99 59
caroline@alizerp.com